Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5136981 | 0.86 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL9920364 | 0.79 | KDM4E (0.39) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL14757965 | 0.79 | RAB9A (0.44) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL1160709 | 0.77 | TSHR (0.42) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL9923415 | 0.76 | KDM4E (0.54) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL14757969 | 0.75 | ALDH1A1 (0.41) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL12066102 | 0.75 | KDM4E (0.41) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL5137204 | 0.75 | MAP4K4 (0.45) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL358541 | 0.73 | ALDH1A1 (0.40) | KDM4EALDH1A1HSD17B10HPGDPOLB | |
| SCHEMBL5148646 | 0.71 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013033093-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011150356-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011014817-A1 | PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | KDM4E 449/4885ALDH1A1 1632/4885HSD17B10 2734/4885 |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | KDM4E 396/4885ALDH1A1 1654/4885HSD17B10 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.